Dr. Tawbi on the Utilization of Relatlimab and Nivolumab in Metastatic Melanoma

Source: OncLive, April 2022

Hussein A. Tawbi, MD, PhD, director of Melanoma Clinical Research and Early Drug Development and Personalized Cancer Therapy, deputy chair and professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the utilization of relatlimab plus nivolumab (Opdualag) in unresectable or metastatic melanoma.

The phase 2/3 RELATIVITY-047 trial (NCT03470922) evaluated the efficacy of relatlimab in combination with nivolumab vs nivolumab alone in the treatment of metastatic melanoma.

In March of 2022, the FDA approved the fixed-dose combination of relatlimab plus nivolumab in patients 12 years of age or older with unresectable or metastatic melanoma, based on the data from RELATIVITY-047.